Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in Kansas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 23 | 1,163 | 20% |
| 2020 | 21 | 1,114 | 23% |
| 2021 | 23 | 1,139 |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 63% of the cases CMS names in Kansas; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| LAA occlusion & loop recorders | 56 | 2,663+15%/yr | +15%/yr | 6.02.1× | 5% | 4,850 in 2030+10%/yr |
| Pacemaker, ICD & CRT implantation |
EP ablation in every state, and its device makers · Every procedure market in Kansas · Every state · Compare with Illinois
| 2024 |
| 1,645 |
| 36% |
| 2025 est. | ≈ 1,950 | – |
| 2026 est. | ≈ 2,110 | – |
| 28% |
| 2022 | 25 | 1,189 | 31% |
| 2023 | 26 | 1,316 | 34% |
| 2024 | 27 | 1,645 | 36% |
| 2025 from claims | – | 1,947 1,786–2,060 | 36% |
| 2026 forecast | – | 2,106 1,853–2,430 | 36% |
| 2027 forecast | – | 2,278 1,947–2,714 | 36% |
| 2028 forecast | – | 2,463 2,055–3,016 | 37% |
| 2029 forecast | – | 2,664 2,176–3,340 | 37% |
| 2030 forecast | – | 2,880 2,308–3,691 | 37% |
In 2025, 21% inpatient hospital, 79% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| +3.6%/yr |
| 3.4 |
| 0% |
| 7,400 in 2030+8.3%/yr |
| Indiana | 62 | 3,095+8.8%/yr | +8.8%/yr | 3.7 | 0% | 5,760 in 2030+11%/yr |
| Michigan | 66 | 2,682+0.7%/yr | +0.7%/yr | 2.6 | 0% | 4,190 in 2030+7.7%/yr |
| Minnesota | 48 | 1,991+7%/yr | +7%/yr | 3.6 | 0% | 4,870 in 2030+16%/yr |
| Missouri | 37 | 1,982+3.6%/yr | +3.6%/yr | 2.7 | 0% | 3,810 in 2030+11%/yr |
| Wisconsin | 48 | 1,918+11%/yr | +11%/yr | 2.8 | 0% | 3,690 in 2030+12%/yr |
| Iowa | 27 | 1,505+14%/yr | +14%/yr | 3.0 | 0% | 2,760 in 2030+11%/yr |
| Nebraska | 15 | 802+7.1%/yr | +7.1%/yr | 2.8 | 0% | 1,560 in 2030+12%/yr |
| South Dakota | 5 | 296+14%/yr | +14%/yr | 2.0 | 0% | 610 in 2030+13%/yr |
| North Dakota | 5 | 223+7.5%/yr | +7.5%/yr | 2.0 | 0% | 500 in 2030+15%/yr |
| 48 |
| 2,322−5%/yr |
| −5%/yr |
| 5.91.1× |
| 13% |
| 2,470 in 2030+1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Johnson & Johnson MedTech leads with 45% of company spending on these surgeons in 2025, −14 pts on 2024.
In 2025, 5 companies reported engagement with Kansas’s surgeons worth $261K in consulting, speaking, meals and travel tied to these products, about $9,678 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.